Multivariate analysis for TRM, relapse, and treatment failure (inverse of LFS) in adult AML patients who underwent HLA-identical sibling (MRD) HCT or 8/8 or 7/8 MUD HCT from 2002-2006
| . | TRM, RR (95% CI)* . | P . | Relapse, RR (95% CI)† . | P . | Treatment failure (death or relapse), RR (95% CI)‡ . | P . |
|---|---|---|---|---|---|---|
| 8/8 MUD vs MRD | 1.11 (0.90-1.37) | 0.31 | 0.93 (0.78-1.09) | .37 | 0.98 (0.86-1.12) | .77 |
| 7/8 MUD vs MRD | 1.48 (1.16-1.89) | 0.001 | 0.78 (0.63-0.98) | .03 | 1.02 (0.86-1.20) | .77 |
| 7/8 MUD vs 8/8 MUD | 1.33 (1.09-1.62) | 0.004 | 0.84 (0.69-1.03) | .10 | 1.04 (0.91-1.20) | .55 |
| . | TRM, RR (95% CI)* . | P . | Relapse, RR (95% CI)† . | P . | Treatment failure (death or relapse), RR (95% CI)‡ . | P . |
|---|---|---|---|---|---|---|
| 8/8 MUD vs MRD | 1.11 (0.90-1.37) | 0.31 | 0.93 (0.78-1.09) | .37 | 0.98 (0.86-1.12) | .77 |
| 7/8 MUD vs MRD | 1.48 (1.16-1.89) | 0.001 | 0.78 (0.63-0.98) | .03 | 1.02 (0.86-1.20) | .77 |
| 7/8 MUD vs 8/8 MUD | 1.33 (1.09-1.62) | 0.004 | 0.84 (0.69-1.03) | .10 | 1.04 (0.91-1.20) | .55 |
Other significant factors include KPS, disease status at transplantation, cytogenetic findings at diagnosis, preceding MDS, and female donor into male recipient.
Other significant factors include disease status at transplantation, cytogenetic findings at diagnosis, WBC at diagnosis, and female donor into male recipient.
Other significant factors include KPS, disease status at transplantation, cytogenetic findings at diagnosis, and preceding MDS.